Left Brain Wealth Management LLC Sells 144 Shares of Moderna, Inc. (NASDAQ:MRNA)

Left Brain Wealth Management LLC reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,401 shares of the company’s stock after selling 144 shares during the quarter. Left Brain Wealth Management LLC’s holdings in Moderna were worth $338,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ogorek Anthony Joseph NY ADV bought a new position in shares of Moderna during the fourth quarter valued at about $27,000. Arlington Trust Co LLC boosted its holdings in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Moderna by 32.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after purchasing an additional 116 shares during the period. Parkside Financial Bank & Trust boosted its holdings in shares of Moderna by 44.9% during the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock worth $58,000 after purchasing an additional 175 shares during the period. Finally, Sachetta LLC purchased a new stake in shares of Moderna during the fourth quarter worth about $56,000. 75.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MRNA shares. Evercore ISI started coverage on shares of Moderna in a report on Tuesday, May 14th. They set an “in-line” rating and a $120.00 target price for the company. HSBC reiterated a “reduce” rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Royal Bank of Canada increased their target price on shares of Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a report on Monday, June 3rd. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Monday, June 3rd. Finally, Canaccord Genuity Group raised their price objective on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus price target of $128.02.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 705 shares of Moderna stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the completion of the sale, the chief financial officer now owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Moderna news, President Stephen Hoge sold 255 shares of Moderna stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the sale, the president now owns 1,486,508 shares of the company’s stock, valued at approximately $179,808,007.68. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO James M. Mock sold 705 shares of Moderna stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the completion of the sale, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The disclosure for this sale can be found here. Insiders sold 218,245 shares of company stock valued at $26,083,172 over the last 90 days. Corporate insiders own 15.20% of the company’s stock.

Moderna Stock Down 0.3 %

Shares of MRNA traded down $0.50 on Tuesday, hitting $148.09. 925,761 shares of the stock traded hands, compared to its average volume of 4,218,659. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The business has a 50 day simple moving average of $125.52 and a 200 day simple moving average of $106.69. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.19 earnings per share. On average, equities analysts forecast that Moderna, Inc. will post -7.46 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.